Dendritic cell (DC)-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) is a type II C-type lectin expressed on DCs such as myeloid DCs and monocyte-derived DCs (MoDCs)
Dendritic cells (DCs) play a critical role in initiating adaptive immunity by uptaking foreign antigens at the periphery, undergoing maturation during migration to lymph nodes and presenting antigen-derived peptides to naïve T cells (1, 2) . For effective recognition of antigens, DCs exploit a wide range of pattern recognition receptors (PRRs) such as Toll-like receptors and C-type lectins (3) (4) (5) . DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN; CD209) is a type II transmembrane C-type lectin expressed on myeloid DCs in the dermis, mucosae, lymph nodes and monocyte-derived DCs (MoDCs) (6, 7) . DC-SIGN binds to "self" glycan ligands found on human cells and to "foreign" glycans of bacterial or parasitic pathogens, and specifically recognizes glycoconjugates containing mannose (Man), fucose (Fuc), and nonsialylated Lewis (Le) structures in a Ca 2+ -dependent manner (8) . Through recognition of these glycans, DC-SIGN functions as an adhesion receptor, and mediates the binding and internalization of foreign pathogens such as viruses (human immunodeficiency virus and hepatitis C virus), yeasts, bacteria (Mycobacterium tuberculosis), and parasites (3) .
Recently, we and another group found that DC-SIGN recognizes colorectal carcinoma cells through carcinoembryonic antigen (CEA) (9, 10) . DC-SIGN-binding CEA contained tumor-associated Le glycans, which were important for cellular interactions between DCs and colorectal carcinoma cells in situ. It is evident that the expression of CEA is limited and can be detected only in cancer and embryonic tissues. This glycoprotein is one of the most widely used tumor markers for gastrointestinal cancers such as colorectal carcinomas. However, its sensitivity and specificity are not high, particularly for early stages of the disease such as Duke's A or B stages. Based on our studies, we hypothesized that DC-SIGN may also be involved in the recognition of other glycoproteins, as novel potential biomarkers, expressed on colorectal cancers.
In this study, we firstly identified Mac-2-binding protein (Mac-2BP) expressed on colorectal carcinoma cells as a novel DC-SIGN ligand through affinity chromatography and mass spectrometry. Mac-2BP, also known as 90K or galectin-3BP, is a secretory glycoprotein expressed on various normal epithelial cells and in human bodily fluids. It has been reported that the level of Mac-2BP increases in patients with pancreatic, breast and lung cancer, virus infections such as acquired immunodeficiency syndrome and hepatitis C, and autoimmune diseases (11) . However, most of the immunological significance of Mac-2BP on colorectal carcinomas remains unknown.
In addition, we found that DC-SIGN-dependent cellular interactions between immature MoDCs and colorectal carcinoma cells mainly expressing Mac-2BP were able to significantly inhibit LPS-induced MoDC functional maturation. Furthermore, we also detected Mac-2BP as a predominant DC-SIGN ligand expressed on some primary colorectal cancer tissues from certain parts of patients in comparison with CEA from the other parts. Therefore, we suggest that Mac-2BP carrying fucosylated glycans may become a novel potential colorectal cancer biomarker for some CEA-low or -negative colorectal cancer patients, and the novel function of DC-SIGN may, at least in part, underlie for its potential use as a novel diagnostic sensor for some colorectal cancer patients through recognition of CEA and Mac-2BP. 
EXPERIMENTAL PROCEDURES

Reagents and antibodies-
ELISA analysis-
For analysis of DC-SIGN binding to proteins secreted by HLF, COLO205 or SW1116 cells, culture supernatants were mixed with coating buffer (Na 2 CO 3 buffer, pH 9.6), and then coated onto NUNC maxisorp 96-well plates (Nalge Nunc) overnight at 4℃. Mannan was used as a positive control. Then the plates were blocked with 3% BSA in coating buffer for 1 h at room temperature, washed with TBS, pH 7.6, containing 0.05% Tween 20, and then incubated with 0.4 µg/ml rhDC-SIGN-FLAG in 1% BSA in TBS, pH 7.6, containing 5 mM CaCl 2 for 1 h at room temperature. After the plates had been washed, HRP conjugated anti-FLAG mAb was added, followed by incubation for 1 h. For analysis of DC-SIGN binding to Mac-2BP secreted by human hepatoma and colorectal carcinoma cell lines, 1 µg/ml anti-Mac-2BP pAbs were precoated onto 96-well plates overnight at 4℃. After blocking, culture supernatants of HepG2, HLF, COLO205, LS180 or SW1116 cells were added, followed by incubation for 1 h at room temperature. DC-SIGN binding was assayed using rhDC-SIGN-FLAG, as described above. For quantitative kinetic data of association between DC-SIGN and Mac-2BP, 5 ng/well of Mac-2BP captured onto plates were reacted for 2 h with different concentrations (0.063-8.000 nM) of rhDC-SIGN-FLAG in the presence of 5 mM CaCl 2 . Quantitative kinetic data (Kd and Bmax) were calculated based on the amounts of total and unbound rhDC-SIGN-FLAG using a nonlinear regression model by GraphPad Prism 4.0c software.
DC-SIGN was regarded as a tetramer. For determination of the glycan profile of COLO205-derived Mac-2BP, anti-Mac-2BP pAb was precoated onto 96-well plates overnight at 4℃. After blocking, culture supernatants of HLF or COLO205 cells were added, followed by incubation for 1 h at room temperature. Then the captured Mac-2BP was incubated with biotin-conjugated plant lectins [Phytohaemagglutinin (PHA)-L4, Lycopersicon esculentum agglutinin (LEA) and Aleuria aurantia agglutinin (AAL)], followed by incubation with HRP-conjugated avidin. After development, binding was quantitated by measuring the absorbance at 450 nm using a Multilabel Counter (PerkinElmer, Wellesley, MA) in accordance with the manufacturer's instructions. All experiments were performed in triplicate and were repeated a minimum of three times. Preparation of membrane fractions, affinity chromatography, and mass spectrometryAffinity sepharoses were prepared using Seize X Protein G Immunoprecipitation Kit (Thermo Fisher Scientific, Inc). According to manufacturer's instructions, rhDC-SIGN-Fc and hIgG-Fc proteins were immobilized to the Protein G sepharose using the cross-linker disuccinimidyl suberate (DSS). Cells were homogenized in homogenization buffer [10 mM Tris-HCl (pH 7.6), 0.5 mM MgCl 2 , and protease inhibitor cocktail] and then tonicity was restored into 150 mM NaCl. The homogenate was centrifuged at 500 ×g for 5 min at 4°C to remove cell debris and nuclei. The supernatant was supplemented with EDTA to 5 mM and then centrifuged at 150,000 ×g for 45 min at 4°C. The resulting total membrane pellet was solubilized with lysis buffer [150 mM NaCl, 20 mM Tris/HCl (pH 7.5), 1 mM EDTA, 1% Triton X-100, and protease inhibitor cocktail] for 60 min at 4°C and then centrifuged at 10,000 ×g for 60 min at 4°C. The supernatant was saved as the solubilized COLO205 membrane proteins and was applied to a rhDC-SIGN-Fc or hIgG-Fc affinity column. After the column had been washed with TBS buffer (pH 7.5) containing 5 mM CaCl 2 and 0.1% Triton X-100, the proteins bound to the column were eluted with TBS buffer (pH 7.5) containing 10 mM EDTA and 0.1% Triton X-100. The EDTA-eluted fractions were buffer-exchanged, applied again to the same column and then eluted with TBS buffer (pH 7.5) containing 50 mM Man. The secondly eluted proteins were resolved on a 5-20% Tris-HCl gradient gel (ATTO Corporation) and then stained with a silver staining kit (Wako Purre Chemical Industries). Bands were excised from the gel and subjected to in-gel digestion. The peptides released from the gel were subjected to liquid chromatography (LC)/MS/MS with a linear ion trap mass spectrometer (LTQ, Thermo Fisher Scientific Inc., Waltham, MA, USA) interfaced on-line with a nano HPLC (Paradigm, Michrom BioResources, Auburn, CA, USA). The eluents consisted of H 2 O containing 2% CH 3 CN and 0.1% formic acid (Pump A), and 90% CH 3 CN and 0.1% formic acid (Pump B), and the peptides were eluted with a linear gradient of 5-80% from Pump B. Data-dependent MS/MS acquisition was performed for the most intense ions as precursors. Proteins were identified by searching the Swiss-prot Homo sapiens and NCBInr database (human) using the Mascot search engine (Matrixscience, London, UK) and Bioworks search engine (Thermo Fisher Scientific, Inc.), respectively.
Ligand-precipitation, immunoprecipitation and immunoblotting-
Solubilized membrane proteins from HLF, COLO205 and SW1116 cells were prepared as described above, and used as ligand-precipitation, immunoprecipitation and immunoblot samples. To identify the proteins carrying DC-SIGN carbohydrate ligands on colorectal carcinomas, precipitation was performed using rhDC-SIGN-Fc-or rhIgG-Fc-ProteinG beads, and the bound proteins were eluted with EDTA as immunoblot samples. The samples were resolved on 5-20% gradient SDS-PAGE gels (ATTO Corporation), and then transferred to nitrocellulose membranes, followed by immunoblot detection with specific antibodies. For visualization, a SuperSignal West Pico Chemiluminescent kit (Thermo Fisher Scientific) was used with HRP-conjugated anti-mouse or anti-goat IgG. The amounts of SDS-PAGE loading proteins from HLF, COLO205 and SW1116 cells were adjusted on the basis of cell numbers, and we confirmed by Bradford method that whole membrane lysates contained 15-20 µg/lane and culture supernatant contained 27-32 µg/lane of comparable proteins (data not shown).
Glycan digestion assay-
For peptide-N-glycosidase (PNGase) F treatment, membrane proteins prepared from COLO205 cells, as described above, were adjusted to 10 mM EDTA, 0.1 % SDS and 0.1 % NP-40, and then incubated overnight with or without PNGase F at 37℃. After replacement in Hepes buffer (pH 7.5)-0.15 M NaCl by ultrafiltration, DC-SIGN ligands were precipitated with rhDC-SIGN-Fc, followed by SDS-PAGE and immunobloting with anti-Mac-2BP pAb. For α1-3, 4 fucosidase treatment, a membrane pellet of COLO205 cells prepared as described above was suspended in 20 mM KH 2 PO 4 (pH 5.0) buffer containing 1% NP-40, followed by incubation overnight with or without α1-3, 4-fucosidase at 37℃, and then ligand-precipitation with rhDC-SIGN-Fc, anti-Le a or -Le b mAb, SDS-PAGE, and immunobloting with anti-Mac-2BP pAb.
MoDC functional maturation-
To determine the effect of a MoDC-COLO205-cocultured supernatant on LPS-induced functional maturation of MoDCs, immature MoDCs were incubated in a MoDC-cultured, or MoDC-SW1116-cocultured supernatant for 3 days in the presence of IL-4 (500 U/ml), GM-CSF (800 U/ml), and LPS (1 ng/ml). Supernatant of MoDC, which cultured in the presence of anti-DC-SIGN pAb, was used as a control. Cultures were replenished with fresh supernatant on the second day. The effect on MoDC functional maturation was determined by cell-surface expression of CD83, a DC-specific maturation marker, and CD86, a costimulatory molecule on mature DCs, using FACS Calibur TM , and the mean fluorescent intensity (MFI) was calculated with CELLQUEST software TM (BD Biosciences, San Diego, CA). All experiments were performed in triplicate and were repeated a minimum of three times.
Hhistochemistry-
Clinical colorectal cancer tissue specimens were purchased from SuperBioChips Laboratories (Seoul, Korea), or obtained from Shiga University of Medical Science with informed consent. This project was approved by the ethics committee of Shiga University of Medical Science. Following deparaffinization and hydration of paraffin-embedded tissue sections, antigen retrieval was performed by steaming in citrate buffer (pH 6.0). After blocking with 1% BSA, the slides were incubated with 1µg/ml of anti-Mac-2BP pAb followed by Alexa Fluor 546-conjugated secondary antibody (Ab) (for anti-Mac-2BP staining), anti-CEA mAb (1:50) followed by Alexa Fluor 488-conjugated secondary Ab (for anti-CEA staining), and/or 1µg/ml of APC-conjugated rhDC-SIGN-FLAG (for direct rhDC-SIGN staining, donor 1) or rhDC-SIGN-FLAG followed by anti-FLAG mAb and Alexa Fluor 488-conjugated secondary Ab (for indirect rhDC-SIGN staining, donor 2), and then washed and mounted. To observe the expression of DC-SIGN ligands on COLO205 cells, cells were stained with 1µg/ml of rhDC-SIGN-APC and anti-Mac-2BP pAb, followed by Alexa Fluor 488-conjugated secondary Ab in the presence of CaCl 2 
Statistical analysis-
The results are expressed as the means ± S.D. of data obtained in three experiments performed in duplicate or triplicate. Statistical significance was determined by means of Student's t-test. To completely isolate DC-SIGN ligands expressed on COLO205, the ligand glycoproteins from solubilized membrane fractions were purified by an affinity column of recombinant human DC-SIGN-Fc (rhDC-SIGN-Fc), and then analyzed by nano-LC/MS/MS, as described under Experimental Procedures. The two major silver-stained bands, which were independent of the Fc portion of the DC-SIGN-Fc chimaeric protein, indicated by the arrows (Fig. 1B) from rhDC-SIGN-Fc column were identified as matured and degraded Mac-2BP, respectively (Fig. 1C) .
RESULTS
DC-SIGN-mediated cellular adhesions and
On the other hand, we previously identified CEA as the main DC-SIGN ligand expressed on SW1116 cells, another human colorectal carcinoma cell line. Therefore, we compared the expression levels of Mac-2BP and CEA between COLO205 and SW1116 cells by confocal microscopy. As shown in Fig. 1D , the cell-surface expression of Mac-2BP was markedly higher on COLO205 than SW1116 cells. In contrast, CEA could hardly be detected on COLO205 cells compared with its abundant expression on SW1116 cells.
Next, to confirm the interaction of DC-SIGN with Mac-2BP in vitro, DC-SIGN ligands purified from COLO205, SW1116 and human hepatoma HLF cells were immunoblotted with anti-Mac-2BP pAb (Fig. 1E ) or anti-CEA mAb (Fig. 1F) . The results showed that COLO205-derived Mac-2BP, but not HLF or SW1116-derived Mac-2BP, apparently interacted with rhDC-SIGN (Fig. 1E) . In contrast, we observed high-level expression of CEA on SW1116 cells and its distinct association with rhDC-SIGN (Fig. 1F) , whereas we could not detect any association of COLO205-derived CEA with rhDC-SIGN. Confocal microscopy also showed that Mac-2BP (green) was substantially colocalized with APC-fluoresceinated rhDC-SIGN (red) on COLO205 cells in a Ca 2+ -dependent manner (Fig.  1G) .
These findings indicated that Mac-2BP is a novel DC-SIGN ligand expressed on colorectal carcinoma cells and that DC-SIGN selectively interacts with Mac-2BP expressed on particular carcinoma cells as opposed to CEA.
DC-SIGN binds to Mac-2BP secreted by several colorectal carcinoma cell lines.
Mac-2BP and CEA were originally known as secretory proteins. Therefore, we examined whether or not DC-SIGN ligands existed in COLO205-, SW1116-or HLF-cultured supernatants. As shown in Fig. 2A (Fig. 2B) . On the other hand, CEA, which can interact with DC-SIGN, was only observed in the SW1116-cultured supernatant (Fig. 2C) . Moreover, we investigated the interaction of DC-SIGN with Mac-2BP secreted by several other human hepatoma and colorectal carcinoma cell lines (Fig. 2D) . The ELISA data showed that the human hepatoma HepG2 and HLF, and human colorectal carcinoma COLO205, LS180 and SW1116 cell lines all apparently expressed Mac-2BP (Fig. 2D, upper) , however, only the COLO205-and LS180-derived Mac-2BP had the ability to interact with rhDC-SIGN (lower), indicating that parts of colorectal carcinomas can secrete DC-SIGN-recognizing Mac-2BP. These results also suggest that distinct glycoforms of Mac-2BP exist in different colorectal carcinomas. Moreover, their affinity level was shown to be extremely high when the apparent dissociation constant [Kd= 2.50 (±0.66)] was calculated by fitting a curve using nonlinear regression model (Fig.  3B) . These results suggest the potential physiological interaction between DC-SIGN and Mac-2BP in the colon microenvironment.
DC-SIGN binds to Mac-2BP from colorectal carcinoma cells in Ca
DC-SIGN recognizes the fucose residues of Le N-glycans on Mac-2BP from colorectal carcinoma cells.
To determine whether or not interaction of Mac-2BP with DC-SIGN is N-glycan-dependent, Mac-2BP purified from COLO205 cells was treated with PNGase F, and then precipitated with rhDC-SIGN. Fig. 4A shows that the Mac-2BP band shifted from 90 kDa to 65kDa on PNGase F treatment, and that the PNGase F-treated form had completely lost the ability to bind rhDC-SIGN, indicating that the N-glycans on Mac-2BP mediate the interaction with DC-SIGN.
We next examined whether or not DC-SIGN-binding Mac-2BP expresses characteristic glycans by ELISA involving commonly used plant lectins (Fig. 4B) . Well-coated Mac-2BP was incubated with three plant lectins, PHA-L4, LEA and AAL, respectively. LEA, which predominantly recognizes polylactosamine glycans, exhibited a high degree of binding to HLF-derived Mac-2BP and a low degree of binding to COLO205-derived Mac-2BP. Whereas PHA-L4, which recognizes β1-6 branched GlcNAc glycans, exhibited almost the same degree of binding to HLFand COLO205-derived Mac-2BPs, suggesting that β1-6 branched GlcNAc glycans are not the direct moieties for DC-SIGN binding. Interestingly, fucose-binding AAL lectin exhibited much stronger affinity with COLO205-derived than HLF-derived Mac-2BP.
AAL lectin exhibits a high affinity for α-fucosyl residues in the cores of N-linked glycans and Le glycans such as Le Fig. 4C , the defucosylated Mac-2BP had almost completely lost the ability to interact with DC-SIGN. Confocal microscopy also showed that Mac-2BP (red) significantly expresses Le b glycans (green) on COLO205 cells (Fig. 4D) . These results suggest that DC-SIGN is selective in its recognition of specific types of fucosylated N-glycans, and that these N-glycans expressed on DC-SIGN-binding Mac-2BP are important for the interaction.
DC-SIGN mediates cellular adhesion between immature MoDCs and COLO205 cells.
Next, to determine whether or not immature DCs interact with COLO205 cells through DC-SIGN, we prepared MoDCs from human peripheral blood monocytes and cocultured them with COLO205 cells. As shown in Fig. 5A , MoDCs were found to stably adhere to COLO205 cells and to form large agglutinations when they were cocultured (middle), compared with a MoDC culture control (left). The addition of anti-DC-SIGN pAb partially blocked the MoDC-COLO205 interactions and agglutinations (right), indicating that DC-SIGN mediated the interactions and agglutinations. Furthermore, confocal microscopy demonstrated that immature MoDCs expressed a remarkable level of DC-SIGN (green) at the points of contact with COLO205 cells expressing both Mac-2BP (upper) and Le b (lower) (red) (Fig. 5B) . These results, also considering the results of Fig. 4 , C and D, suggest that Mac-2BP carrying Le b glycans is involved in the association between MoDCs and colorectal cancer cells in situ.
DC-SIGN-mediated cellular adhesion between immature MoDCs and COLO205 cells attenuates MoDC maturation
We previously demonstrated that the MoDC-SW1116 adhesion mediated by the glycosylation-dependent interactions between DC-SIGN and CEA resulted in dysfunctional MoDCs (9,10). To determine whether or not this observation is also caused by the DC-SIGN-Mac-2BP interaction, we examined the effect of MoDC-COLO205 coculture condition on MoDC functional maturation. A coculture-derived supernatant was prepared from cocultures of COLO205 carcinoma cells and MoDCs after LPS stimulation. The addition of the MoDC-COLO205 coculture-derived supernatant to a new MoDC culture led to inhibition of maturation marker CD83 and activation marker CD86 expression compared with a MoDC culture-derived control supernatant (Fig. 6, A and B) , suggesting that interaction between MoDCs and COLO205 cells causes suppression of LPS-induced functional maturation of MoDCs. Direct stimulation of MoDC with anti-DC-SIGN pAb also significantly suppressed MoDC maturation, suggesting that DC-SIGN signaling cascade is sufficiently involved in MoDC maturation pathways.
Collectively, our results indicate that the DC-SIGN-dependent interaction with COLO205-derived Mac-2BP as well as that with SW1116-derived CEA induces cellular adhesion between MoDCs and colorectal carcinoma cells, which impairs MoDC functional maturation.
Mac-2BP is a major DC-SIGN ligand in some primary colorectal carcinoma tissues.
To determine whether or not DC-SIGN recognizes Mac-2BP in situ, human normal and malignant colon tissues from the same patients were double stained with rhDC-SIGN and anti-Mac-2BP pAb (Fig. 7A) . As reported previously (12) , Mac-2BP expression in malignant tissues was high in about half of the patients at mucosal epithelia compared with in normal tissues. Moreover, the staining pattern in the rhDC-SIGN markedly overlapped that of the Mac-2BP in the malignant epithelia (Fig. 7A) , indicating that Mac-2BP, as a novel DC-SIGN ligand, is highly expressed on primary cancer colon epithelia and implying that DC-SIGN is involved in the association between DCs and colorectal cancer cells in situ through recognition of these cancer-related Le glycan ligands.
We and another group have recently reported that DC-SIGN recognizes CEA expressed in colorectal cancer tissues of patients (9, 10) . Therefore, to next examine the differences in expression pattern of and association with rhDC-SIGN between CEA and Mac-2BP, we performed triple staining with rhDC-SIGN, anti-Mac-2BP pAb and anti-CEA mAb. In contrast to the CEA localization limited on the apical face of cancer epithelia, the Mac-2BP expression exhibited a more defuse pattern on both the apical and basolateral faces of epithelia in malignant colorectal cancer tissues, and little expression of either CEA or Mac-2BP was observed in colorectal normal tissues (Fig. 7B) . Additionally, as shown in Fig. 7B , colorectal cancer patients could be divided into Mac-2BP Table 1 . These results indicate that Mac-2BP may become a novel potential colorectal cancer biomarker for some patients with CEA-low or -negative colorectal cancer.
DISCUSSION
During the neoplastic process in colon tissues, genetic or epigenetic gene alteration often accompanies changes in cell-surface glycans. Glycosylation changes during malignant transformation lead to tumor-specific carbohydrate structures that interact with C-type lectins on dendritic cells. In general, these changes have been associated with a poor prognosis, as they are linked to the aggressiveness and metastatic capacity of tumors. Good examples of heavily glycosylated tumor antigens are CEA and CEACAM1 (13) (14) (15) (16) (17) (18) (19) , which can be secreted or expressed by colon cancer cells. Because the function of dendritic cells may be dependent on their binding properties as to self-antigens and pathogens, it is essential to obtain a detailed insight into the carbohydrate-binding properties of DC-SIGN.
Previous research indicated that tumor cells with their surface decorated with β1-6-branched N-linked oligosaccharides acquire invasiveness and metastatic potential through a change in the affinity level to the extracellular microenvironment (20, 21) . Mac-2BP expressed on colorectal carcinoma cells was initially identified as a L-PHA-recognized major glycoprotein bearing polylactosamine glycans extending from β1-6 branched N-linked oligosaccharides (22, 23) . In this study, we have firstly identified Mac-2BP on colorectal carcinoma cells as a novel ligand for C-type lectin DC-SIGN, and demonstrated the Ca 2+ -dependent interaction of rhDC-SIGN with Mac-2BP from colorectal carcinoma COLO205 cells. Generally, DC-SIGN exhibits dual specificities for high-mannose as well as Le-type glycans (8, 24, 25) . Foreign antigens recognized by DC-SIGN have both types of glycans. Whereas, so far, most endogenous ligands for DC-SIGN have been found to carry only Le-type glycans. Here we showed that specific removal of Le glycans on Mac-2BP by α1-3, 4 fucosidase abrogated these interactions, indicating that the fucose moieties of Le glycans are required for the interactions. We also observed that DC-SIGN ligands are highly expressed with Le a or Le b glycans on human colorectal carcinoma cells (Figs. 4C and  5D ), suggesting that increased expression of DC-SIGN ligands on colorectal cancer cells in addition to altered glycosylation results in recognition by DC-SIGN, and that further fucosylation of polylactosamine glycans and formation of Le epitopes on Mac-2BP during cancer progression may be important for induction of the interaction between DC-SIGN and Mac-2BP. In addition, we also found that the expression levels of Le epitopes were positively correlated with the staining levels with rhDC-SIGN in 30 colorectal carcinoma cell lines including LoVo, LS513, LS174T, SNU1197, etc. (data not shown).
CEA is one of the most widely used tumor markers for gastrointestinal cancer such as colorectal carcinomas. It has been pointed out that the change in distribution of CEA from apical into basolateral and stromal areas in malignant colorectal cancer tissues could be a cause of its entry into the blood and elevation of the serum CEA level (14, 16) . However, the sensitivity and specificity of CEA are considered to be low, particularly for early stages of the disease such as Duke's A or B stages (26) . We showed here that the distribution of Mac-2BP was more basolateral than that of CEA and that expression of Mac-2BP in primary colon adenocarcinoma tissues was increased compared to in proximal normal tissues, and obtained various staining patterns for Mac-2BP such as luminal staining, and punctate staining on the apical and basolateral faces (Fig. 7B ). In addition, we observed here that DC-SIGN greatly associated with not only CEA but also Mac-2BP on the apical face of cancer epithelia and that DC-SIGN retained responsiveness to Mac-2BP in more basolateral areas. Since basolateral expression of Mac-2BP has been reported to be more prevalent in early-stage Duke's A tumors than in advanced ones (12) , DC-SIGN may preferably recognize early-stage colorectal carcinoma cells through Mac-2BP. Therefore, similarly to that of CEA, aberrant expression of Mac-2BP and its polar breakdown in cancer tissues may allow its entry into blood vessels. Furthermore, it is also interesting that the type of Mac-2BP secreted by several colorectal carcinoma cells had DC-SIGN-detectable glycan structures, whereas we did not detect any binding of DC-SIGN to serum Mac-2BP from healthy donors (data not shown), suggesting that DC-SIGN can qualitatively distinguish colorectal carcinoma-derived Mac-2BP from serum Mac-2BP in normal and cancer patients.
Recent evidence indicates that dendritic cell-associated DC-SIGN may have functions in both the induction of tolerance to self-antigens and the recognition of pathogens, respectively. A variety of cytokines, including IL-6, IL-10 and macrophage colony-stimulating factor (M-CSF), have been shown to affect the maturation of DCs from CD34 precursors and from MoDCs in vitro (27, 28) . Failure of the immune system to provide protection against tumor cells is an important immunological problem. It is now evident that inadequate functioning of the host immune system is one of the main mechanisms by which tumors escape from immune control, as well as an important factor that limits the success of cancer immunotherapy. In recent years, it has become increasingly clear that defects in DCs play a crucial role in non-responsiveness to tumors (29). Here we showed that DC-SIGN-dependent cellular interactions between immature MoDCs and colorectal carcinoma cells significantly inhibited MoDC functional maturation, suggesting that, similar to CEA, Mac-2BP bearing colorectal tumor-associated Le glycans may provide a tolerogenic microenvironment for colorectal carcinoma cells through interactions with DC-SIGN. These findings also imply that the glycosylation-dependent cellular interactions may result in suppression of DC functions, possibly through immunosuppressive cytokines such as IL-6 and IL-10, and that production of these immunosuppressive factors in DC-tumor coculture supernatants may be one of the mechanisms by which tumors evade immunosurveillance.
Recently, the intracellular signaling mechanisms of DC-SIGN were elucidated (30) (31) (32) . DC-SIGN constitutively associates with a signalosome complex consisting of scaffold protein LSP1 and mediates crosstalk with TLR signaling, which results in modulation of TLR-induced cytokine responses. Indeed, interaction of foreign pathogens such as Mycobacterium tuberculosis leads to upregulation of LPS-induced IL-10 and suppress MoDC maturation (33) . Therefore, the MoDC maturation as a consequence of DC-SIGN interacting with Le glycans of cancer cells may also be mediated through a series of LSP1-associated intracellular signaling pathway. MoDCs, following sensitization with CEA-derived peptides ex vivo, are now utilized as a tool for the clinical applications of tumor immunotherapies. Since the immunogenicities of peptide vaccines vary among patients who exhibit different immune responsiveness which is defined by means of HLA types etc., appropriate selection of antigens is needed individually to obtain adequate therapeutic benefit. In this context, colorectal carcinoma-derived Mac-2BP, similar to CEA, might become a candidate new cancer vaccine. Canceling of tumor-escaping mechanisms, such as DC-SIGN-mediated MoDC dysfunction, by combination of therapeutic agents which target intracellular signaling molecules (e.g., LSP1) may be a critical step for maintaining the effective tumor-immunogenicity in the future.
In conclusion, based on the distinct expression patterns of Mac-2BP and CEA together with the DC-SIGN recognition model presented here, colorectal cancer patients could be divided into 
